Ascendis Pharma ADR (ASND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Sales | 63,593 | 38,766 | 104,112 | 148,657 | 52,280 |
| Cost of Goods | 12,317 | 12,347 | 8,218 | 20,950 | 8,041 |
| Gross Profit | 51,277 | 26,420 | 95,895 | 127,707 | 44,239 |
| Operating Expenses | 157,972 | 170,271 | 149,469 | 167,599 | 190,569 |
| Operating Income | -106,379 | -143,505 | -53,357 | -38,942 | -146,289 |
| Interest Expense | 27,872 | 21,133 | 83,774 | 265 | 26,687 |
| Other Income | 26,294 | 47,093 | -2,411 | -47,556 | -2,886 |
| Pre-tax Income | -107,957 | -117,545 | -139,542 | -86,763 | -175,862 |
| Income Tax | 1,122 | 247 | 2,723 | 6,278 | 702 |
| Net Income Continuous | -109,078 | -117,791 | -142,265 | -93,041 | -176,564 |
| Net Income | $-109,078 | $-117,791 | $-142,265 | $-93,041 | $-176,564 |
| EPS Basic Total Ops | -1.89 | -2.06 | -2.50 | -1.64 | -3.14 |
| EPS Basic Continuous Ops | -1.90 | -2.05 | -2.50 | -1.64 | -3.14 |
| EPS Diluted Total Ops | -1.89 | -2.06 | -2.50 | -1.64 | -3.14 |
| EPS Diluted Continuous Ops | -1.90 | -2.05 | -2.50 | -1.64 | -3.14 |
| EPS Diluted Before Non-Recurring Items | -1.89 | -2.05 | -2.48 | N/A | N/A |
| EBITDA(a) | $-101,368 | $-138,818 | $-48,496 | $-33,641 | $-141,145 |